SUBSCRIBERS
GSK shutting down Biopolis neural unit
Other ongoing investments here not affected; UK pharma giant remains committed to R&D in Singapore
Published Fri, Dec 5, 2014 · 09:50 PM
Singapore
IN a move to cut costs, United Kingdom pharma giant GlaxoSmithKline (GSK) will begin a phased closure of its operations at its neural pathways discovery performance unit at Biopolis, following its global review to refocus the global pharmaceuticals business.
While it declined to reveal the number of employees…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
German forecast to offer signs if ailing economy on the mend
PBOC steps up rhetoric against long-end government bond rally
Trade, TikTok, Taiwan: Blinken faces tough talks in China
Australian inflation boosts case for higher-for-longer rates
The American small-business tyrant has a favourite political party
China’s prices are just too low for buyers to sweat about tariffs